The minimum criteria for a valid report determine when received information can be processed regulatorily as an individual case safety report. An identifiable reporter, an identifiable patient, at least one adverse reaction, and a suspected medicinal product are required; if any of these four elements are missing, the case is considered incomplete.
The Four Required Elements
The reporting person must be identifiable so that their existence and, if necessary, follow-up queries are traceable. Similarly, the affected patient must be distinguishable as a real person based on sufficient information. ICH E2D cites, for example, age or age group, gender, initials, date of birth, name, or a patient identification number. Not every single one of these values is mandatory, but the information must not be completely detached from an individual.
In addition to the reporter and patient, the report must contain an adverse reaction and name a suspected product. These four criteria do not create a complete medical case description. Rather, they mark the threshold at which information can be processed as a regulatorily relevant individual case. Details regarding the course of events, dose, concomitant medication, or pre-existing conditions may be essential for assessment, but they do not belong to this minimum threshold.
Incomplete Cases and Follow-up
The absence of a criterion does not end the responsibility of the marketing authorization holder. ICH E2D expects missing information to be sought with due diligence. The receipt of a fragmentary communication is therefore documented, and the source is contacted specifically for patient data, reaction, product, or reporter details wherever possible. Follow-up does not serve to artificially complete a case, but to clarify whether a genuine individual case exists.
The term ‘identifiable’ refers to the verifiability of the existence of the patient and the primary source. For second-hand information, reasonable steps are required to verify both. This distinguishes a traceable drug safety report from an anonymous allegation, where neither follow-up queries nor assignment to an actually affected human being are possible.
The criteria also apply when the initial information arrives via an intermediary, such as a literature source, a distribution partner, or a healthcare professional. In these constellations, a distinction is made between the initial contact and the primary source. Careful recording of all involved informants facilitates follow-up and prevents the same reaction from being counted multiple times as an independent case.
Distinction from Aggregate Statements and Full Case Narratives
An aggregate statement such as “some patients reported complaints” does not constitute a reportable individual case without patient-related identifiability. Even the mention of a fixed number of affected individuals does not replace the four minimum criteria. Such information should be followed up for patient-specific details before an individual case report is created and forwarded regulatorily.
Conversely, a valid report does not have to contain a full case narrative upon receipt. Completeness, medical assessability, and validity for reporting are different levels of quality. After receipt of a valid minimum, further data is collected for causality assessment, severity, coding, and case processing. The minimum criteria thus prevent both the reporting of mere rumors and the loss of traceable initial information.
They thus form the entry criterion for technical regulatory case processing.
Relevance for clinical trials
In a clinical trial, safety processes often begin with brief information from the study site, an email, or a phone call. The safety data team must quickly recognize whether the message contains the four criteria and request missing information in a structured manner. Clear recording of the contact person and the affected study participant prevents follow-up reports from being incorrectly assigned to the same or another case. Even with confirmed validity for reporting, the distinction between an adverse event, reaction, and SUSAR remains a separate professional decision.
Full-service CROs like Mediconomics provide support regarding the minimum criteria for valid reports through triage rules for incoming safety information, case creation in the safety database, and quality-assured follow-up requests to study sites. They align training and standard operating procedures so that study personnel capture the four data points during the initial report and provide missing information specifically, without preempting the medical assessment.
Frequently Asked Questions (FAQ)
Is the statement “several patients” sufficient for a valid report?
No. A fixed or indefinite number does not replace the identifiability of an individual patient. The communication should be followed up until patient-specific information is available or it is clear that it cannot be obtained.
Is an incomplete case meaningless for pharmacovigilance?
No. It is not yet a valid individual case report, but it triggers the obligation to obtain missing minimum information with due diligence. The original information and the follow-up steps are recorded traceably.
Must the patient be known by name?
No. ICH E2D lists several possible identifiers such as age, gender, initials, or a patient identification number. The decisive factor is that the existence of a specific patient is verifiable and the case does not remain just a general aggregate allegation.
Regulatory References
- ICH E2D, Post-Approval Safety Data Management – specifies the four minimum data elements of a regulatorily reportable ADR report and follow-up expectations.
- ICH E2D(R1), Post-Approval Safety Data Management – describes minimum criteria, identifiability, and the handling of cases without complete information.
- EMA, GVP Module VI – covers the collection, processing, and reporting of suspected adverse reactions.
- Implementing Regulation (EU) No 520/2012 – sets out Union requirements for pharmacovigilance data and its transmission.